Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond poorly to vaccination. Relative deficits in immunity are, however, unclear, especially after 3 vaccine doses. We evaluated immune responses in hematology patients across three COVID-19 vaccination doses. Seropositivity was low after a first dose of BNT162b2 and ChAdOx1 (∼26%), increased to 59%-75% after a second dose, and increased to 85% after a third dose. While prototypical antibody-secreting cells (ASCs) and T follicular helper (Tfh) cell responses were elicited in healthy participants, hematology patients showed prolonged ASCs and skewed Tfh2/17 responses. Importantly, vaccine-induced expansions of spike-specific and peptide-HLA tetramer-specific CD4+/CD8+ T cells, together with their T cell receptor (TCR) repertoires, were robust in hematology patients, irrespective of B cell numbers, and comparable to healthy participants. Vaccinated patients with breakthrough infections developed higher antibody responses, while T cell responses were comparable to healthy groups. COVID-19 vaccination induces robust T cell immunity in hematology patients of varying diseases and treatments irrespective of B cell numbers and antibody response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 4(2023), 4 vom: 18. Apr., Seite 101017 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.04.2023 Date Revised 06.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2023.101017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355349493 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355349493 | ||
| 003 | DE-627 | ||
| 005 | 20231226064147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2023.101017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355349493 | ||
| 035 | |a (NLM)37030296 | ||
| 035 | |a (PII)S2666-3791(23)00127-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyen, Thi H O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2023 | ||
| 500 | |a Date Revised 06.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond poorly to vaccination. Relative deficits in immunity are, however, unclear, especially after 3 vaccine doses. We evaluated immune responses in hematology patients across three COVID-19 vaccination doses. Seropositivity was low after a first dose of BNT162b2 and ChAdOx1 (∼26%), increased to 59%-75% after a second dose, and increased to 85% after a third dose. While prototypical antibody-secreting cells (ASCs) and T follicular helper (Tfh) cell responses were elicited in healthy participants, hematology patients showed prolonged ASCs and skewed Tfh2/17 responses. Importantly, vaccine-induced expansions of spike-specific and peptide-HLA tetramer-specific CD4+/CD8+ T cells, together with their T cell receptor (TCR) repertoires, were robust in hematology patients, irrespective of B cell numbers, and comparable to healthy participants. Vaccinated patients with breakthrough infections developed higher antibody responses, while T cell responses were comparable to healthy groups. COVID-19 vaccination induces robust T cell immunity in hematology patients of varying diseases and treatments irrespective of B cell numbers and antibody response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a B cells | |
| 650 | 4 | |a CD4(+) T cells | |
| 650 | 4 | |a CD8(+) T cells | |
| 650 | 4 | |a COVID-19 vaccines | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a T follicular helper cells | |
| 650 | 4 | |a antibody-secreting cells | |
| 650 | 4 | |a hematology | |
| 650 | 4 | |a memory T cells | |
| 650 | 4 | |a tetramer-specific | |
| 650 | 7 | |a Receptors, Antigen, T-Cell, alpha-beta |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 700 | 1 | |a Rowntree, Louise C |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Lilith F |e verfasserin |4 aut | |
| 700 | 1 | |a Chua, Brendon Y |e verfasserin |4 aut | |
| 700 | 1 | |a Kedzierski, Lukasz |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Chhay |e verfasserin |4 aut | |
| 700 | 1 | |a Lasica, Masa |e verfasserin |4 aut | |
| 700 | 1 | |a Tennakoon, G Surekha |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Natalie R |e verfasserin |4 aut | |
| 700 | 1 | |a Crane, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Chee, Lynette |e verfasserin |4 aut | |
| 700 | 1 | |a Seymour, John F |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Mary Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Whitechurch, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Clemens, E Bridie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wuji |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, So Young |e verfasserin |4 aut | |
| 700 | 1 | |a Habel, Jennifer R |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Xiaoxiao |e verfasserin |4 aut | |
| 700 | 1 | |a McQuilten, Hayley A |e verfasserin |4 aut | |
| 700 | 1 | |a Minervina, Anastasia A |e verfasserin |4 aut | |
| 700 | 1 | |a Pogorelyy, Mikhail V |e verfasserin |4 aut | |
| 700 | 1 | |a Chaurasia, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Menon, Tejas |e verfasserin |4 aut | |
| 700 | 1 | |a Hensen, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Neil, Jessica A |e verfasserin |4 aut | |
| 700 | 1 | |a Mordant, Francesca L |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Hyon-Xhi |e verfasserin |4 aut | |
| 700 | 1 | |a Cabug, Aira F |e verfasserin |4 aut | |
| 700 | 1 | |a Wheatley, Adam K |e verfasserin |4 aut | |
| 700 | 1 | |a Kent, Stephen J |e verfasserin |4 aut | |
| 700 | 1 | |a Subbarao, Kanta |e verfasserin |4 aut | |
| 700 | 1 | |a Karapanagiotidis, Theo |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Vo, Lynn K |e verfasserin |4 aut | |
| 700 | 1 | |a Cain, Natalie L |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholson, Suellen |e verfasserin |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Gibney, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a James, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Trevillyan, Janine M |e verfasserin |4 aut | |
| 700 | 1 | |a Trubiano, Jason A |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Jeni |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 700 | 1 | |a Bond, Katherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Williamson, Deborah A |e verfasserin |4 aut | |
| 700 | 1 | |a Rossjohn, Jamie |e verfasserin |4 aut | |
| 700 | 1 | |a Crawford, Jeremy Chase |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Paul G |e verfasserin |4 aut | |
| 700 | 1 | |a Thursky, Karin A |e verfasserin |4 aut | |
| 700 | 1 | |a Slavin, Monica A |e verfasserin |4 aut | |
| 700 | 1 | |a Tam, Constantine S |e verfasserin |4 aut | |
| 700 | 1 | |a Teh, Benjamin W |e verfasserin |4 aut | |
| 700 | 1 | |a Kedzierska, Katherine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 4(2023), 4 vom: 18. Apr., Seite 101017 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:4 |g day:18 |g month:04 |g pages:101017 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2023.101017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 4 |b 18 |c 04 |h 101017 | ||